AU2013324681B2 - Quinazolinone derivatives as PARP inhibitors - Google Patents

Quinazolinone derivatives as PARP inhibitors Download PDF

Info

Publication number
AU2013324681B2
AU2013324681B2 AU2013324681A AU2013324681A AU2013324681B2 AU 2013324681 B2 AU2013324681 B2 AU 2013324681B2 AU 2013324681 A AU2013324681 A AU 2013324681A AU 2013324681 A AU2013324681 A AU 2013324681A AU 2013324681 B2 AU2013324681 B2 AU 2013324681B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
formula
methyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013324681A
Other languages
English (en)
Other versions
AU2013324681A1 (en
Inventor
Hans-Peter Buchstaller
Dieter Dorsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2013324681A1 publication Critical patent/AU2013324681A1/en
Application granted granted Critical
Publication of AU2013324681B2 publication Critical patent/AU2013324681B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013324681A 2012-09-26 2013-08-27 Quinazolinone derivatives as PARP inhibitors Active AU2013324681B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12006707.9 2012-09-26
EP12006707 2012-09-26
PCT/EP2013/002577 WO2014048532A1 (en) 2012-09-26 2013-08-27 Quinazolinone derivatives as parp inhibitors

Publications (2)

Publication Number Publication Date
AU2013324681A1 AU2013324681A1 (en) 2015-05-07
AU2013324681B2 true AU2013324681B2 (en) 2017-08-10

Family

ID=47002492

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013324681A Active AU2013324681B2 (en) 2012-09-26 2013-08-27 Quinazolinone derivatives as PARP inhibitors

Country Status (16)

Country Link
US (1) US9388142B2 (OSRAM)
EP (1) EP2900643B1 (OSRAM)
JP (1) JP6276769B2 (OSRAM)
KR (1) KR102200628B1 (OSRAM)
CN (1) CN104662006B (OSRAM)
AR (1) AR092670A1 (OSRAM)
AU (1) AU2013324681B2 (OSRAM)
BR (1) BR112015006524A8 (OSRAM)
CA (1) CA2886000C (OSRAM)
ES (1) ES2654464T3 (OSRAM)
IL (1) IL237840A (OSRAM)
MX (1) MX362855B (OSRAM)
RU (1) RU2650107C2 (OSRAM)
SG (1) SG11201502120XA (OSRAM)
WO (1) WO2014048532A1 (OSRAM)
ZA (1) ZA201502838B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356509B (es) 2011-12-22 2018-05-30 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2597757T3 (es) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Nucleósidos de uracilespirooxetano
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
JP6456392B2 (ja) 2013-09-11 2019-01-23 インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用
EP3206689B1 (en) 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN107286169B (zh) * 2016-04-05 2020-11-24 北京四环制药有限公司 端锚聚合酶抑制剂
CN106432103A (zh) * 2016-09-14 2017-02-22 信阳师范学院 一种喹唑酮类化合物及其制备方法
WO2018204176A1 (en) * 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
EP3733206A4 (en) * 2017-12-27 2021-12-01 Japanese Foundation For Cancer Research ANTI-CANCER AGENTS
ES2998084T3 (en) * 2017-12-27 2025-02-19 Japanese Found For Cancer Res Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
JP2022546010A (ja) * 2019-08-28 2022-11-02 エフ．ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス疾患の処置及び予防のための新規キナゾリン化合物
WO2025111705A1 (en) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors
WO2025221809A1 (en) * 2024-04-16 2025-10-23 Eluciderm Inc. 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054132A1 (de) * 1980-12-12 1982-06-23 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
WO1995024379A1 (en) * 1994-03-09 1995-09-14 Newcastle University Ventures Limited Benzamide analogs, useful as parp (adp-ribosyltransferase, adprt) dna repair enzyme inhibitors
WO1998033802A1 (en) * 1997-02-01 1998-08-06 Newcastle University Ventures Limited Quinazolinone compounds
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
WO2012028578A1 (de) * 2010-09-03 2012-03-08 Bayer Cropscience Ag Substituierte anellierte pyrimidinone und dihydropyrimidinone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046871A1 (de) * 1980-12-12 1982-07-22 Dr. Karl Thomae Gmbh, 7950 Biberach Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999018077A1 (en) 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
MX2007010965A (es) * 2005-03-09 2007-09-19 Merck & Co Inc Antagonistas de canales de calcio de tipo t de quinazolinona.
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
CN105859639A (zh) * 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054132A1 (de) * 1980-12-12 1982-06-23 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
WO1995024379A1 (en) * 1994-03-09 1995-09-14 Newcastle University Ventures Limited Benzamide analogs, useful as parp (adp-ribosyltransferase, adprt) dna repair enzyme inhibitors
WO1998033802A1 (en) * 1997-02-01 1998-08-06 Newcastle University Ventures Limited Quinazolinone compounds
WO2004014873A1 (ja) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
WO2012028578A1 (de) * 2010-09-03 2012-03-08 Bayer Cropscience Ag Substituierte anellierte pyrimidinone und dihydropyrimidinone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COSTANTINO, G. et al., JOURNAL OF MEDICINAL CHEMISTRY (2001), Vol. 44, No. 23, Pages 3786-3794 *
LAYEVA, A. A. et al., RUSSIAN CHEMICAL BULLETIN (2007), Vol. 56, No. 9, Pages 1821-1827 *
WEI, X. et al, ORGANIC LETTERS (2011), Vol. 13, No. 6, Pages 1274-1277 *

Also Published As

Publication number Publication date
ES2654464T3 (es) 2018-02-13
KR20150063474A (ko) 2015-06-09
CA2886000C (en) 2020-11-10
AR092670A1 (es) 2015-04-29
RU2015115576A (ru) 2016-11-20
CA2886000A1 (en) 2014-04-03
AU2013324681A1 (en) 2015-05-07
HK1210777A1 (en) 2016-05-06
MX362855B (es) 2019-02-20
RU2650107C2 (ru) 2018-04-09
CN104662006B (zh) 2017-10-24
SG11201502120XA (en) 2015-04-29
KR102200628B1 (ko) 2021-01-08
US9388142B2 (en) 2016-07-12
MX2015003570A (es) 2015-06-22
IL237840A (en) 2017-05-29
CN104662006A (zh) 2015-05-27
EP2900643A1 (en) 2015-08-05
US20150239850A1 (en) 2015-08-27
BR112015006524A2 (pt) 2017-07-04
JP6276769B2 (ja) 2018-02-07
ZA201502838B (en) 2017-11-29
EP2900643B1 (en) 2017-09-27
WO2014048532A1 (en) 2014-04-03
BR112015006524A8 (pt) 2019-08-20
JP2015535831A (ja) 2015-12-17

Similar Documents

Publication Publication Date Title
AU2013324681B2 (en) Quinazolinone derivatives as PARP inhibitors
AU2013301870B2 (en) (Aza-)isoquinolinone derivatives
AU2013257018B2 (en) Pyrrolotriazinone derivatives
AU2013242492B2 (en) Bicyclic pyrazinone derivatives
AU2013218357B2 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
AU2014301669B2 (en) Phthalazine derivatives
HK1210777B (en) Quinazolinone derivatives as parp inhibitors
HK1209106B (en) (aza-)isoquinolinone derivatives
HK1202551B (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
HK1205740B (en) Pyrrolotriazinone derivatives
HK1203961B (en) Bicyclic pyrazinone derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)